Stephens Inc. AR Has $1.13 Million Stake in Pacira Pharmaceuticals, Inc. (PCRX)

Stephens Inc. AR lessened its position in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 3.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,775 shares of the company’s stock after selling 901 shares during the period. Stephens Inc. AR owned about 0.06% of Pacira Pharmaceuticals worth $1,134,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of PCRX. Teachers Advisors LLC raised its holdings in shares of Pacira Pharmaceuticals by 6.2% during the fourth quarter. Teachers Advisors LLC now owns 62,854 shares of the company’s stock valued at $2,030,000 after purchasing an additional 3,658 shares during the last quarter. Nationwide Fund Advisors raised its holdings in shares of Pacira Pharmaceuticals by 147.4% during the first quarter. Nationwide Fund Advisors now owns 56,190 shares of the company’s stock valued at $2,562,000 after purchasing an additional 33,482 shares during the last quarter. Capital Fund Management S.A. purchased a new position in shares of Pacira Pharmaceuticals during the first quarter valued at approximately $300,000. US Bancorp DE raised its holdings in shares of Pacira Pharmaceuticals by 50.5% during the first quarter. US Bancorp DE now owns 8,989 shares of the company’s stock valued at $410,000 after purchasing an additional 3,015 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Pacira Pharmaceuticals by 4.2% during the first quarter. Bank of New York Mellon Corp now owns 206,435 shares of the company’s stock valued at $9,415,000 after purchasing an additional 8,366 shares during the last quarter.

Several research analysts have recently weighed in on PCRX shares. Canaccord Genuity set a $60.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 22nd. Royal Bank Of Canada set a $58.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, July 30th. Mizuho reissued a “buy” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. HC Wainwright set a $59.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Needham & Company LLC started coverage on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. They set a “buy” rating and a $55.00 price objective for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $52.92.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 3,461 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the transaction, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at approximately $783,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul J. Hastings sold 1,044 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The disclosure for this sale can be found here. Insiders have sold a total of 33,390 shares of company stock valued at $1,215,480 over the last three months. 6.60% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Stephens Inc. AR Has $1.13 Million Stake in Pacira Pharmaceuticals, Inc. (PCRX)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/09/17/stephens-inc-ar-has-1-13-million-stake-in-pacira-pharmaceuticals-inc-pcrx.html.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) opened at 37.05 on Friday. Pacira Pharmaceuticals, Inc. has a one year low of $29.95 and a one year high of $58.95. The firm’s 50-day moving average is $37.12 and its 200-day moving average is $44.48. The stock’s market capitalization is $1.49 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The company had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the business earned $0.21 earnings per share. On average, analysts expect that Pacira Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply